US20090137572A1 - 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders - Google Patents

2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders Download PDF

Info

Publication number
US20090137572A1
US20090137572A1 US11/596,740 US59674005A US2009137572A1 US 20090137572 A1 US20090137572 A1 US 20090137572A1 US 59674005 A US59674005 A US 59674005A US 2009137572 A1 US2009137572 A1 US 2009137572A1
Authority
US
United States
Prior art keywords
thiazol
methyl
pyrimidin
phenyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/596,740
Other languages
English (en)
Inventor
Shudong Wang
Gavin Wood
Kenneth Duncan
Christopher Meades
Darren Gibson
Janice McLachlan
Peter Martin Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Assigned to CYCLACEL LIMITED reassignment CYCLACEL LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WANG, SHUDONG
Assigned to CYCLACEL LIMITED reassignment CYCLACEL LIMITED CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTORS WOOD, DUNCAN, MEADES, GIBSON, MCLACHLAN AND FISCHER WERE INADVERTENTLY OMITTED FROM THE ORIGINAL FILING. PREVIOUSLY RECORDED ON REEL 021837 FRAME 0501. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNORS HEREBY CONVEY ASSIGNMENT OF ENTIRE INTEREST.. Assignors: MCLACHLAN, JANICE, GIBSON, DARREN, WANG, SHUDONG, FISCHER, PETER MARTIN, DUNCAN, KENNETH, MEADES, CHRISTOPHER, WOOD, GAVIN
Publication of US20090137572A1 publication Critical patent/US20090137572A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to new 2-substituted-4-heteroaryl-pyrimidine derivatives and their use in therapy. More specifically, the invention relates to 2-substituted-4-heteroaryl-pyrimidine derivatives having improved solubility properties.
  • CDKs cyclin-independent protein kinases
  • 2-phenylamino-heteroaryl-pyrimidines possess selective in vitro and in vivo antiproliferative activity against a range of human tumour cells (Wang S, Blake D, Clarke R, Duff S, McClue S J, McInnes C, Melville J, Stewart K, Taylor P, Westwood R, Wood G, Wu S-Y, Zhelev N Z, Zheleva D I, Walkinshaw M, Lane D P, Fischer P M. Proc. Amer. Assoc. Cancer Res. 2002; 43: 4202).
  • the present invention seeks to provide further 2-substituted-4-heteroaryl-pyrimidines. More specifically, the present invention preferably seeks to provide 2-substituted-4-heteroaryl-pyrimidines which display improved aqueous solubility and/or bioavailability.
  • a first aspect of the invention relates to a compound selected from compounds [1]-[220] as set forth in Table 1, or a pharmaceutically acceptable salt thereof.
  • the present compounds are equipped with solubilising functions on the phenyl and/or heteroaryl rings of the 2-phenylamino-4-heteroaryl-pyrimidine system. Modification with solubilising moieties has preserved the desired in vitro biological activity (inhibition of CDKs and cytotoxicity against transformed human cells) and in some cases has led to surprising and unexpected increases in potency. Furthermore, in vivo absorption, and oral bioavailability in particular can also be improved using the solubilising strategies presented herein.
  • a second aspect of the invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof,
  • one of X 1 and X 2 is S, and the other of X 1 and X 2 is N;
  • Z is NH, NHCO, NHCOCH 2 , NHSO 2 , NHCH 2 , CH 2 , CH 2 CH 2 , CH ⁇ CH, O, S, SO 2 , or SO;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently H, alkyl, alkyl-R 9 , aryl, aryl-R 9 , aralkyl, aralkyl-R 9 , halogeno, NO 2 , CN, OH, O-alkyl, COR 9 , COOR 9 , O-aryl, O—R 9 , NH 2 , NH-alkyl, NH-aryl, NH(aralkyl), N-(alkyl) 2 , N-(aryl) 2 , N-(alkyl)(aryl), NH—R 9 , N—(R 9 )(R 10 ), N-(alkyl)(R 9 ), N-(aryl)(R 9 ), COOH, CONH 2 , CONH-alkyl, CONH-aryl, CON-(alkyl)(R 9 ), CON(aryl)(R
  • a third aspect of the invention relates to a compound of formula II, or a pharmaceutically acceptable salt thereof,
  • one of X 1 and X 2 is S, and the other of X 1 and X 2 is N;
  • Z is NH, NHCO, NHCOCH 2 , NHSO 2 , NHCH 2 , CH 2 , CH 2 CH 2 , CH ⁇ CH, O, S, SO 2 , or SO;
  • R 1 , R 3 , R 4 , R 5 , R 6 and R 7 and R 8 are each independently H, alkyl, alkyl-R 9 , aryl, aryl-R 9 , aralkyl, aralkyl-R 9 , halogeno, NO 2 , CN, OH, O-alkyl, COR 9 , COOR 9 , O-aryl, O—R 9 , NH 2 , NH-alkyl, NH-aryl, NH(aralkyl), N-(alkyl) 2 , N-(aryl) 2 , N-(alkyl)(aryl), NH—R 9 , N—(R 9 )(R 10 ), N-(alkyl)(R 9 ), N-(aryl)(R 9 ), COOH, CONH 2 , CONH-alkyl, CONH-aryl, CON-(alkyl)(R 9 ), CON(aryl)(R 9 ), CONH
  • a fourth aspect of the invention relates to pharmaceutical compositions comprising the above described compounds admixed with a pharmaceutically acceptable diluent, excipient or carrier.
  • a fifth aspect of the invention relates to the use of the above described compounds in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a stroke, diabetes, a CNS disorder and alopecia.
  • a sixth aspect of the invention relates to the use of the above described compounds for inhibiting a protein kinase.
  • a seventh aspect of the invention relates to the use of the above described compounds in an assay for identifying further candidate compounds capable of inhibiting a protein kinase.
  • alkyl includes both straight chain and branched alkyl groups having from 1 to 8 carbon atoms, e.g. methyl, ethyl propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl etc. and the term “lower alkyl” is similarly used for groups having from 1 to 4 carbon atoms.
  • aryl refers to a substituted (mono- or poly-) or unsubstituted monoaromatic or polyaromatic system, wherein said polyaromatic system may be fused or unfused.
  • aryl is includes groups having from 6 to 10 carbon atoms, e.g. phenyl, naphthyl etc.
  • aryl is synonymous with the term “aromatic”.
  • aralkyl is used as a conjunction of the terms alkyl and aryl as given above.
  • Preferred aralkyl groups include CH 2 Ph and CH 2 CH 2 Ph and the like.
  • alicyclic refers to a cyclic aliphatic group.
  • aliphatic takes its normal meaning in the art and includes non-aromatic groups such as alkanes, alkenes and alkynes and substituted derivatives thereof.
  • carbohydrate derivative refers to a compound of general formula C x (H 2 O) y or a derivative thereof.
  • the carbohydrate is a a mono-, di- or tri-saccharide.
  • Monosaccharides can exist as either straight chain or ring-shaped molecules and are classified according to the number of carbon atoms they possess; trioses have three carbons, tetroses four, pentoses five and hexoses six. Each of these subgroups may be further divided into aldoses and ketoses, depending on whether the molecule contains an aldehyde group (—CHO) or a ketone group (C ⁇ O).
  • Typical examples of monosaccharides include glucose, fructose, and galactose.
  • Disaccharides consist of two linked monosaccharide molecules, and include for example, maltose and lactose.
  • Trisaccharides consist of three linked monosaccharide molecules.
  • derivative as used herein includes chemical modification of an entity. Illustrative of such chemical modifications would be replacement of hydrogen by a halo group, an alkyl group, an acyl group or an amino group.
  • heterocycle refers to a saturated or unsaturated cyclic group containing one or more heteroatoms in the ring.
  • heteroaryl refers to a heterocyclic group that is aromatic.
  • the compound is selected from the following:
  • the compound is selected from the following:
  • one aspect of the invention relates to compounds of formula I as defined above, or pharmaceutically acceptable salts thereof.
  • the compounds of formula I bear a mono- or di-substituted thiazol-3-yl or thiazol-5-yl radical attached to the pyrimidine ring through one of the ring carbon atoms
  • the heterocycle is a thiazol-5-yl group.
  • X 1 is S and X 2 is N.
  • R 1 and R 2 are each independently selected from alkyl, NH 2 and NH-alkyl, N-(alkyl) 2 and N-(alkyl)(aryl).
  • R 1 and R 2 are each independently selected from alkyl, NH 2 and NH-alkyl.
  • R 1 is selected from methyl, NH 2 , NHMe and NHEt, and R 2 is methyl. More preferably still, R 1 is Me.
  • At least one of R 2 , R 5 , R 6 or R 7 is an R 9 or R 10 -containing group, or is R 11 .
  • X 1 is S
  • X 2 is N
  • Z is NH
  • R 1 is Me
  • R 2 is alkyl or amino
  • R 3 is H
  • one or two of R 5 , R 6 , and R 7 are CF 3 , OH, O-alkyl, halogeno, NO 2 , NH 2 , NH-alkyl or N-(alkyl) 2 and at least one of R 2 , R 5 , R 6 or R 7 is an R 9 or R 10 -containing group, or is R 11 .
  • At least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 is R 11 .
  • R 11 is a solubilising group as defined for R 9 and R 10 in (i)-(iv) above, or (v)-(xiv) as defined above.
  • R 11 is a solubilising group as defined for R 9 and R 10 in (i)-(iv) above, or (v)-(vii), (ix)-(xiv) as defined above, or is selected from:
  • the solubilising group is R 11 and is:
  • the solubilising group is R 11 , and R 11 is:
  • Y is an alicyclic group comprising one or more of the functions —O—, —N—, NH 2 , —NH—, ⁇ N—, a quarternary amine salt, or amidine, and wherein Y is optionally substituted by one or more substituents as defined above.
  • Y is other than pyridinyl.
  • Y is a morpholinyl or piperazinyl group, each of which may be optionally substituted by one or more substituents selected from SO 2 -alkyl, alkyl optionally substituted by one or more OH groups, CO-alkyl, aralkyl, COO-alkyl, and an ether group optionally substituted by one or more OH groups
  • Y is a 2-oxo-hexahydro-thien[3,4-d]imidazole group.
  • At least one of R 2 , R 6 or R 7 is R 11 .
  • R 11 is selected from the following:
  • R 6 or R 7 is R 11 . More preferably, R 6 is R 11 and R 2 , R 4 , R 5 , R 7 and R 8 are each independently selected from alkyl, H, CF 3 , OH, O-alkyl, halogeno, NO 2 , NH 2 , NH-alkyl and N-(alkyl) 2 . More preferably still, R 6 is R 11 and R 2 , R 4 , R 5 , R 7 and R 8 are each independently selected from alkyl, H, O-alkyl, halogeno, NO 2 , NH 2 and NH-alkyl. Even more preferably, R 6 is R 11 and R 4 , R 5 , R 7 and R 8 are all H and R 2 is selected from alkyl, O-alkyl, NH 2 and NH-alkyl.
  • R 11 is selected from:
  • R 7 is R 11 and R 4 , R 5 , R 6 , R 8 are all H, and R 2 is selected from alkyl, O-alkyl, NH 2 and NH-alkyl.
  • R 11 is selected from:
  • At least one of R 2 or R 6 is R 11 .
  • R 11 is preferably selected from the following:
  • R 6 is R 11 .
  • R 6 is R 11
  • R 2 , R 4 , R 5 , R 7 and R 8 are each independently selected from alkyl, H, CF 3 , OH, O-alkyl, halogeno, NO 2 , NH 2 , NH-alkyl and N-(alkyl) 2 .
  • R 2 , R 4 , R 5 , R 7 and R 8 are each independently selected from alkyl, H, O-alkyl, halogeno, NO 2 , NH 2 and NH-alkyl.
  • R 4 , R 5 , R 7 and R 8 are all H and R 2 is selected from alkyl, O-alkyl, NH 2 and NH-alkyl.
  • R 11 is selected from:
  • R 2 is R 11 .
  • R 2 is R 11 , preferably R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from alkyl, H, CF 3 , OH, O-alkyl, halogeno, NO 2 , NH 2 , NH-alkyl and N-(alkyl) 2 .
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, O-alkyl, halogeno, N-(alkyl) 2 , NO 2 .
  • one of R 5 or R 7 is selected from NO 2 , alkoxy, halogeno and N-(alkyl) 2 , and the remainder of R 4 , R 5 , R 6 , R 7 and R 8 are all H.
  • R 11 is selected from:
  • R 3 is H.
  • R 1 is methyl
  • Z is NH
  • R 3 is H.
  • Z is NH
  • Z is NHCOCH 2 .
  • R 2 is N(alkyl) 2 , NH-alkyl, alkyl, more preferably NMe 2 , NHEt or Me.
  • R 3 is H and R 1 is alkyl, more preferably Me.
  • R4-8 are each independently selected from H, NO 2 , alkoxy and halogen, more preferably H, NO 2 , chloro and OMe.
  • Z is —NH— and at least one of R 4 -R 8 is selected from (CH 2 ) n′′ NR 17 COR 18 and SO 2 NR 19 R 20 .
  • Z is —NH— and at least one of R 4 -R 8 is N-piperidinyl, N-pyrrolidinyl or N-thiomorpholinyl, each of which may be optionally substituted by one or more alkyl, alkoxy or CO-alkyl groups.
  • R 1 is alkyl, more preferably Me, and R 3 is H.
  • R 1 is alkyl, NH 2 , NH-alkyl, hydroxy-substituted alkyl or pyridinyl, more preferably, Me, NH 2 , NHEt, CH 2 OH or 3-pyridinyl.
  • R 4 -R 8 are each independently selected from H, alkyl and alkoxy, more preferably, H, Me and OMe. More preferably still, R 6 is N-piperidinyl, N-pyrrodinyl or N-thiomorpholinyl, R 7 is H, Me or OMe, and R 4 , R 5 and R 8 are all H.
  • At least one of R 4 -R 8 is selected from
  • Z is —NH—, one of R 6 and R 7 is selected from:
  • N-piperidinyl, N-pyrrolidinyl and N-thiomorpholinyl each of which may be optionally substituted by one or more alkyl, alkoxy or CO-alkyl groups; and the other of R 6 and R 7 is H, alkyl or alkoxy, preferably, H, Me or OMe.
  • Z is —NH— and two of R 4 -R 8 are linked to form a cyclic ether containing one or more oxygens.
  • R 6 and R 7 are linked to form a cyclic ether containing one or more oxygens.
  • R 4 , R 5 and R 8 are H.
  • R 2 is NH-alkyl, NH 2 , pyridinyl or NH-aralkyl, more preferably NHEt, NH 2 , 3-pyridinyl or NHCH 2 CH 2 Ph.
  • R 1 is alkyl, more preferably Me.
  • R 6 and R 7 are linked to form a cyclic ether as shown below
  • At least one of R 6 and R 7 is (CH 2 ) n′′ NR 17 COR 18 or SO 2 NR 19 R 20 .
  • At least one of R 4 -R 8 is (CH 2 ) n′′ NR 17 COR 18 .
  • n′′ is 1, R 17 is H and R 18 is phenyl or pyridinyl.
  • At least one of R 4 -R 8 is SO 2 NR 19 R 20 .
  • At least one of R 4 -R 8 is selected from
  • CH 2 NHCOPh CH 2 NHCO-pyridinyl, SO 2 NHCOMe, SO 2 NHCH 2 Ph, SO 2 NHMe, SO 2 NHC(Me) 2 CH 2 OH, SO 2 NH i Pr, SO 2 NHEt, SO 2 NEt 2 , SO 2 NHCH 2 CH 2 OH and SO 2 NHCH 2 CH 2 OMe.
  • R 4 , R 5 and R 8 are all H, one of R 6 and R 7 is selected from the following:
  • R 4 , R 5 , R 7 and R 8 are all H and R 6 is SO 2 NHCH 2 CH 2 OMe.
  • R 2 is selected from aryl, aryl-R 9 , NH 2 , NH(alkyl), alkyl, N(alkyl) 2 ) 2 , N(alkyl)CO-alkyl, N(alkyl)(aryl), NH(aryl), CH 2 OH, wherein said alkyl and aryl groups are optionally substituted by one or more alkoxy, halo, CF 3 or R 11 groups.
  • R 2 is selected from NH 2 , NHMe, N(Me(Et), NHEt, NH t Bu, Me, NHCH 2 CH 2 OMe, NMe 2 , CH 2 OH, NHPh,
  • Another aspect of the invention relates to compounds of formula Ia, or pharmaceutically acceptable salts thereof,
  • X 1 and X 2 are S, and the other of X 1 and X 2 is N;
  • Z is NH, NHCO, CONH-alkyl, NHSO 2 , NHCH 2 , CH 2 , CH 2 CH 2 , CH ⁇ CH, SO-alkyl, SO 2 -alkyl, SO 2 , SO, S or O;
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently H, alkyl, alkyl-R 9 , aryl, aryl-R 9 , aralkyl, aralkyl-R 9 , halogeno, NO 2 , CN, OH, O-alkyl, COR 9 , COOR 9 , O-aryl, O—R 9 , NH 2 , NH-alkyl, NH-aryl, N-(alkyl) 2 , N-(aryl) 2 , N-(alkyl)(aryl),
  • Y is selected from an alicyclic, aromatic, or heterocyclic group comprising one or more of the functions ⁇ N—, —O—, —NH 2 , —NH—, a quarternary amine salt, guanidine, and amidine, where Y is optionally substituted by one or more substituents selected from:
  • At least one of R 6 and R 7 is (CH 2 ) n′′ NR 17 COR 18 or SO 2 NR 19 R 20 .
  • At least one of R 4 -R 8 is (CH 2 ) n′′ NR 17 COR 18 . More preferably, n′′ is 1, R 17 is H and R 18 is phenyl.
  • At least one of R 4 -R 8 is SO 2 NR 19 R 20 .
  • At least one of R 4 -R 8 is selected from
  • R 4 , R 5 and R 8 are all H, R 6 is H or Me and R 7 is selected from the following:
  • R 4 , R 5 , R 7 and R 8 are all H and R 6 is SO 2 NHCH 2 CH 2 OMe.
  • the compound of formula I is selected from compounds [9], [21], [22], [26], [29], [30]-[33], [36]-[41], [43], [52]-[56], [62]-[78], [80]-[82], [84], [91]-[98], [102], [110], [177]-[181], [183], [193]-[195], [197]-[199], [201]-[209] and [216].
  • the compound of formula Ia is selected from the following:
  • Another aspect of the invention relates to compounds of formula II as defined above, or pharmaceutically acceptable salts thereof.
  • R 1 , R 3-6 , R 7-8 , Z, X 1 , X 2 are as set forth above in respect of compounds of formula I.
  • R 2 is selected from pyridinyl, N(methyl)pyridinyl, NH(aralkyl) and N(methyl)(aralkyl), wherein said pyridinyl or aralkyl groups may be optionally substituted by one or more alkyl, CF 3 or ether groups.
  • R 2 is selected from N(Me)CH 2 Ph, NHCH 2 CH 2 Ph, NHCH 2 Ph,
  • R 6 is an alicyclic group selected from
  • R 4 , R 5 , R 7 and R 8 are each independently selected from H, alkyl, alkoxy and halo. More preferably, R 4 , R 5 , R 7 and R 8 are all H.
  • R 6 or R 7 is CH 2 NHCOMe.
  • the remainder of R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from H, alkyl, alkoxy and halo. More preferably, the remainder of R 4 , R 5 , R 6 , R 7 and R 8 are all H.
  • the compound of formula II is selected from compounds [99], [100], [101], [103], [104]-[109], [117]-[119], [122], [126], [127], [153], [156], [158] and [162]-[165].
  • the compound of the invention is capable of exhibiting an antiproliferative effect in human cell lines, as measured by a standard 72 h MTT cytotoxicity assay.
  • the compound of the invention exhibits an IC 50 value of less than 10 ⁇ M, more preferably less than 5 ⁇ M, even more preferably less than 1 ⁇ M as measured by said MTT assay. More preferably still, the compound exhibits an IC 50 value of less than 0.5 less ⁇ M, more preferably still less than 0.2 ⁇ M.
  • the compound of the invention is capable of inhibiting one or more protein kinases, as measured by the assays described in the accompanying Examples section.
  • the compound of the invention exhibits an IC 50 value of less than 10 ⁇ M, more preferably less than 5 ⁇ M, even more preferably less than 1 ⁇ M or less than 0.5 less ⁇ M, more preferably still less than 0.1 ⁇ M.
  • the compound exhibits an IC 50 value of less than 0.01 ⁇ M.
  • the compound is selected from compound numbers [5]-[7], [13], [18]-[ 28 ], [ 30 ], 31 ], [ 34 ], [ 35 ], [ 38 ]-[40] and [44]-[49] of Table 1.
  • the compound exhibits an IC 50 value of less than 0.005 ⁇ M.
  • the compound is selected from compound numbers [5], [6], [19]-[22], [24], [26]-[28], [31], [34], [35], [39], [40] and [48] of Table 1.
  • the compound exhibits an IC 50 value of less than 0.002 ⁇ M.
  • the compound is selected from compound numbers [19], [20], [27], [28], [35] and [40] of Table 1. More preferably still, the compound is compound [27].
  • the compound of the invention is selected from compound numbers [59] and [138].
  • the compound of the invention is selected from compound numbers [19], [27], [34], [37], [38], [55] and [59].
  • the compound of the invention exhibits a selectivity for inhibiting one or more particular kinases over one or more other kinases.
  • the compound of the invention exhibits a selectivity for inhibiting one or more protein kinases selected from a CDK, GSK, aurora and VEGFR2 over other one or more other kinases.
  • the compound of the invention exhibits a selectivity for a CDK, GSK, aurora kinase or VEGFR2 over one or more other kinases of at least 2-fold, more preferably at least 5-fold, more preferably still at least 10-fold, even more preferably at least 25-fold or 50-fold.
  • the compounds of the invention have been found to possess anti-proliferative activity and are therefore believed to be of use in the treatment of proliferative disorders such as cancers, leukaemias and other disorders associated with uncontrolled cellular proliferation such as psoriasis and restenosis.
  • one aspect of the invention relates to the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a proliferative disorder.
  • preparation of a medicament includes the use of one or more of the above described compounds directly as the medicament in addition to its use in a screening programme for further anti-viral and/or antiproliferative agents or in any stage of the manufacture of such a medicament.
  • an anti-proliferative effect within the scope of the present invention may be demonstrated by the ability to inhibit cell proliferation in an in vitro whole cell assay, for example using any of the cell lines AGS, H1299 or SJSA-1, or by showing inhibition of the interaction between HDM2 and p53 in an appropriate assay.
  • assays including methods for their performance, are described in more detail in the accompanying Examples. Using such assays it may be determined whether a compound is anti-proliferative in the context of the present invention.
  • the proliferative disorder is a cancer or leukaemia.
  • the term proliferative disorder is used herein in a broad sense to include any disorder that requires control of the cell cycle, for example cardiovascular disorders such as restenosis and cardiomyopathy, auto-immune disorders such as glomerulonephritis and rheumatoid arthritis, dermatological disorders such as psoriasis, anti-inflammatory, anti-fungal, antiparasitic disorders such as malaria, emphysema and alopecia.
  • the compounds of the present invention may induce apoptosis or maintain stasis within the desired cells as required.
  • the compounds of the invention may inhibit any of the steps or stages in the cell cycle, for example, formation of the nuclear envelope, exit from the quiescent phase of the cell cycle (G0), G1 progression, chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2 progression, activation of mitotic or meiotic functions, chromosome condensation, centrosome separation, microtubule nucleation, spindle formation and function, interactions with microtubule motor proteins, chromatid separation and segregation, inactivation of mitotic functions, formation of contractile ring, and cytokinesis functions.
  • the compounds of the invention may influence certain gene functions such as chromatin binding, formation of replication complexes, replication licensing, phosphorylation or other secondary modification activity, proteolytic degradation, microtubule binding, actin binding, septin binding, microtubule organising centre nucleation activity and binding to components of cell cycle signalling pathways.
  • the compound of the invention is administered in an amount sufficient to inhibit at least one CDK enzyme.
  • Assays for determining CDK activity are described in more detail in the accompanying examples.
  • a further aspect of the invention relates to a method of treating a CDK-dependent disorder, said method comprising administering to a subject in need thereof, a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above in an amount sufficient to inhibit a CDK.
  • Another aspect relates to the use of a compound of the invention as an anti-mitotic agent.
  • Yet another aspect relates to the use of a compound of the invention for treating a neurodegenerative disorder.
  • the neurodegenerative disorder is neuronal apoptosis.
  • Another aspect of the invention relates to the use of a compound of the invention as an antiviral agent.
  • another aspect of the invention relates to the use of a compound of the invention in the preparation of a medicament for treating a viral disorder, such as human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), human immunodeficiency virus type 1 (HIV-1), and varicella zoster virus (VZV).
  • HCMV human cytomegalovirus
  • HSV-1 herpes simplex virus type 1
  • HSV-1 human immunodeficiency virus type 1
  • VZV varicella zoster virus
  • the compound of the invention is administered in an amount sufficient to inhibit one or more of the host cell CDKs involved in viral replication, i.e. CDK2, CDK7, CDK8, and CDK9 [Wang D, De la Fuente C, Deng L, Wang L, Zilberman I, Eadie C, Healey M, Stein D, Denny T, Harrison L E, Meijer L, Kashanchi F. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 2001; 75: 7266-7279].
  • CDK2 Hos involved in viral replication
  • an anti-viral effect within the scope of the present invention may be demonstrated by the ability to inhibit CDK2, CDK7, CDK8 or CDK9.
  • the invention relates to the use of one or more compounds of the invention in the treatment of a viral disorder which is CDK dependent or sensitive.
  • CDK dependent disorders are associated with an above normal level of activity of one or more CDK enzymes.
  • Such disorders preferably associated with an abnormal level of activity of CDK2, CDK7, CDK8 and/or CDK9.
  • a CDK sensitive disorder is a disorder in which an aberration in the CDK level is not the primary cause, but is downstream of the primary metabolic aberration.
  • CDK2, CDK7, CDK8 and/or CDK9 can be said to be part of the sensitive metabolic pathway and CDK inhibitors may therefore be active in treating such disorders.
  • Another aspect relates to the use of compounds of the invention, or pharmaceutically acceptable salts thereof, in the preparation of a medicament for treating diabetes.
  • the diabetes is type II diabetes.
  • GSK3 is one of several protein kinases that phosphorylate glycogen synthase (GS).
  • GS glycogen synthase
  • Type II diabetes non-insulin dependent diabetes mellitus
  • Hyperglycaemia is due to insulin resistance in the liver, muscles, and other tissues, coupled with impaired secretion of insulin.
  • Skeletal muscle is the main site for insulin-stimulated glucose uptake, there it is either removed from circulation or converted to glycogen.
  • Muscle glycogen deposition is the main determinant in glucose homeostasis and type II diabetics have defective muscle glycogen storage.
  • GSK3 activity is important in type II diabetes [Chen, Y. H.; Hansen, L.; Chen, M. X.; Bjorbaek, C; Vestergaard, H.; Hansen, T.; Cohen, P.
  • GSK3 inhibition is therefore of therapeutic significance in the treatment of diabetes, particularly type H, and diabetic neuropathy.
  • GSK3 is known to phosphorylate many substrates other than GS, and is thus involved in the regulation of multiple biochemical pathways. For example, GSK is highly expressed in the central and peripheral nervous systems.
  • Another aspect therefore relates to the use of compounds of the invention, or pharmaceutically acceptable salts thereof, in the preparation of a medicament for treating a CNS disorders, for example neurodegenerative disorders.
  • a CNS disorder for example neurodegenerative disorders.
  • the CNS disorder is Alzheimer's disease.
  • Tau is a GSK-3 substrate which has been implicated in the etiology of Alzheimer's disease. In healthy nerve cells, Tau co-assembles with tubulin into microtubules. However, in Alzheimer's disease, tau forms large tangles of filaments, which disrupt the microtubule structures in the nerve cell, thereby impairing the transport of nutrients as well as the transmission of neuronal messages.
  • GSK3 inhibitors may be able to prevent and/or reverse the abnormal hyperphosphorylation of the microtubule-associated protein tau that is an invariant feature of Alzheimer's disease and a number of other neurodegenerative diseases, such as progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Mutations in the tau gene cause inherited forms of fronto-temporal dementia, further underscoring the relevance of tau protein dysfunction for the neurodegenerative process [Goedert, M. Curr. Opin. Gen. Dev., 2001, 11, 343].
  • Another aspect relates to the use of compounds of the invention, or pharmaceutically acceptable salts thereof, in the preparation of a medicament for treating bipolar disorder.
  • Yet another aspect relates to the use of compounds of the invention, or pharmaceutically acceptable salts thereof, in the preparation of a medicament for treating a stroke.
  • GSK3 as a pro-apoptotic factor in neuronal cells makes this protein kinase an attractive therapeutic target for the design of inhibitory drugs to treat these diseases.
  • Yet another aspect relates to the use of compounds of the invention, or pharmaceutically acceptable salts thereof, in the preparation of a medicament for treating alopecia.
  • transgenic mice overexpressing a truncated ⁇ -catenin in the skin undergo de novo hair-follicle morphogenesis, which normally is only established during embryogenesis.
  • the ectopic application of GSK3 inhibitors may therefore be therapeutically useful in the treatment of baldness and in restoring hair growth following chemotherapy-induced alopecia.
  • a further aspect of the invention relates to a method of treating a GSK3-dependent disorder, said method comprising administering to a subject in need thereof, a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above in an amount sufficient to inhibit GSK3.
  • the compound of the invention, or pharmaceutically acceptable salt thereof is administered in an amount sufficient to inhibit GSK3 ⁇ .
  • the compound of the invention is administered in an amount sufficient to inhibit at least one PLK enzyme.
  • a further aspect of the invention relates to a method of treating a PLK-dependent disorder, said method comprising administering to a subject in need thereof, a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above in an amount sufficient to inhibit PLK.
  • polo-like kinases constitute a family of serine/threonine protein kinases. Mitotic Drosophila melanogaster mutants at the polo locus display spindle abnormalities [Sunkel et al., J. Cell Sci., 1988, 89, 25] and polo was found to encode a mitotic kinase [Llamazares et al., Genes Dev., 1991, 5, 2153]. In humans, there exist three closely related PLKs [Glover et al., Genes Dev., 1998, 12, 3777].
  • the polo box-dependent PLK1 activity is required for proper metaphase/anaphase transition and cytokinesis [Yuan et al., Cancer Res., 2002, 62, 4186; Seong et al., J. Biol. Chem., 2002, 277, 32282].
  • PLKs regulate some fundamental aspects of mitosis [Lane et al., J. Cell. Biol, 1996, 135, 1701; Cogswell et al., Cell Growth Differ., 2000, 11, 615].
  • PLK1 activity is believed to be necessary for the functional maturation of centrosomes in late G2/early prophase and subsequent establishment of a bipolar spindle.
  • Depletion of cellular PLK1 through the small interfering RNA (siRNA) technique has also confirmed that this protein is required for multiple mitotic processes and completion of cytokinesis [Liu et al., Proc. Natl. Acad. Sci. USA, 2002, 99, 8672].
  • the compound of the invention is administered in an amount sufficient to inhibit PLK1.
  • PLK1 is the best characterized; it regulates a number of cell division cycle effects, including the onset of mitosis [Toyoshima-Morimoto et al., Nature, 2001, 410, 215; Roshak et al., Cell. Signalling, 2000, 12, 405], DNA-damage checkpoint activation [Smits et al., Nat. Cell Biol, 2000, 2, 672; van Vugt et al., J. Biol. Chem., 2001, 276, 41656], regulation of the anaphase promoting complex [Sumara et al., Mol. Cell, 2002, 9, 515; Golan et al., J. Biol.
  • M-phase promoting factor the complex between the cyclin dependent kinase CDK1 and B-type cyclins [Nurse, Nature, 1990, 344, 503].
  • MPF M-phase promoting factor
  • the latter accumulate during the S and G2 phases of the cell cycle and promote the inhibitory phosphorylation of the MPF complex by WEE1, MK1, and MYT1 kinases.
  • WEE1, MK1, and MYT1 kinases At the end of the G2 phase, corresponding dephosphorylation by the dual-specificity phosphatase CDC25C triggers the activation of MPF [Nigg, Nat. Rev. Mol. Cell. Biol., 2001, 2, 21].
  • cyclin B localizes to the cytoplasm [Hagting et al., EMBO J., 1998, 17, 4127], it then becomes phosphorylated during prophase and this event causes nuclear translocation [Hagting et al., Curr. Biol., 1999, 9, 680; Yang et al., J. Biol. Chem., 2001, 276, 3604].
  • the nuclear accumulation of active MPF during prophase is thought to be important for initiating M-phase events [Takizawa et al., Curr. Opin. Cell Biol., 2000, 12, 658].
  • nuclear MPF is kept inactive by WEE1 unless counteracted by CDC25C.
  • the phosphatase CDC25C itself, localized to the cytoplasm during interphase, accumulates in the nucleus in prophase [Seki et al., Mol. Biol. Cell, 1992, 3, 1373; Heald et al., Cell, 1993, 74, 463; Dalai et al., Mol. Cell. Biol., 1999, 19, 4465].
  • the nuclear entry of both cyclin B [Toyoshima-Morimoto et al., Nature, 2001, 410, 215] and CDC25C [Toyoshima-Morimoto et al., EMBO Rep., 2002, 3, 341] are promoted through phosphorylation by PLK1 [Roshak et al., Cell. Signalling, 2000, 12, 405]. This kinase is an important regulator of M-phase initiation.
  • the compounds of the invention are ATP-antagonistic inhibitors of PLK1.
  • ATP antagonism refers to the ability of an inhibitor compound to diminish or prevent PLK catalytic activity, i.e. phosphotransfer from ATP to a macromolecular PLK substrate, by virtue of reversibly or irreversibly binding at the enzyme's active site in such a manner as to impair or abolish ATP binding.
  • the compound of the invention is administered in an amount sufficient to inhibit PLK2 and/or PLK3.
  • PLK2 also known as SNK
  • PLK3 also known as PRK and FNK
  • SNK SNK
  • PLK3 PLK3
  • PLK2 is the least well understood homologue of the three PLKs. Both PLK2 and PLK3 may have additional important post-mitotic functions [Kauselmann et al., EMBO J., 1999, 18, 5528].
  • the compound of the invention is administered in an amount sufficient to inhibit at least one aurora kinase.
  • a further aspect of the invention relates to a method of treating an aurora kinase-dependent disorder, said method comprising administering to a subject in need thereof, a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above in an amount sufficient to inhibit an aurora kinase.
  • the compound of the invention is administered in an amount sufficient to inhibit at least one tyrosine kinase.
  • the tyrosine kinase is Ableson tyrosine kinase (BCR-ABL), FMS-related tyrosine kinase 3 (FLT3), platelet-derived growth factor (PDGF) receptor tyrosine kinase or vascular endothelial growth factor (VEGF) receptor tyrosine kinase.
  • BCR-ABL Ableson tyrosine kinase
  • FLT3 FMS-related tyrosine kinase 3
  • PDGF platelet-derived growth factor
  • VEGF vascular endothelial growth factor
  • a further aspect of the invention relates to a method of treating a tyrosine kinase-dependent disorder, said method comprising administering to a subject in need thereof, a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above in an amount sufficient to inhibit a tyrosine kinase.
  • Another aspect relates to the use of a compound of the invention for inhibiting a protein kinase.
  • a further aspect of the invention relates to a method of inhibiting a protein kinase, said method comprising contacting said protein kinase with a compound of the invention.
  • the protein kinase is selected from a CDK, GSK, an aurora kinase, PLK and a tyrosine kinase.
  • the protein kinase is a cyclin dependent kinase.
  • the protein kinase is CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK8 or CDK9, more preferably CDK2.
  • a further aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention admixed with one or more pharmaceutically acceptable diluents, excipients or carriers.
  • the compounds of the present invention can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent, particularly for human therapy.
  • the pharmaceutical compositions may be for human or animal usage in human and veterinary medicine.
  • Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
  • suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like.
  • suitable diluents include ethanol, glycerol and water.
  • compositions may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).
  • Suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol.
  • Suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition.
  • preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.
  • Antioxidants and suspending agents may be also used.
  • the compounds of the invention can be present as salts or esters, in particular pharmaceutically acceptable salts or esters.
  • salts of the compounds of the invention include suitable acid addition or base salts thereof.
  • suitable pharmaceutical salts may be found in Berge et al, J Pharm Sci, 66, 1-19 (1977). Salts are formed, for example with strong inorganic acids such as mineral acids, e.g.
  • sulphuric acid, phosphoric acid or hydrohalic acids with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid; with aminoacids, for example aspartic or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as (C 1 -C 4 )-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-toluene sulfonic acid.
  • Esters are formed either using organic acids or alcohols/hydroxides, depending on the functional group being esterified.
  • Organic acids include carboxylic acids, such as alkanecarboxylic acids of 1 to 12 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acid, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid; with aminoacids, for example aspartic or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as (C 1 -C 4 )-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-to
  • Suitable hydroxides include inorganic hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide.
  • Alcohols include alkanealcohols of 1-12 carbon atoms which may be unsubstituted or substituted, e.g. by a halogen).
  • the invention includes, where appropriate all enantiomers and tautomers of the compounds of the invention.
  • the person skilled in the art will recognise compounds that possess an optical properties (one or more chiral carbon atoms) or tautomeric characteristics.
  • the corresponding enantiomers and/or tautomers may be isolated/prepared by methods known in the art.
  • Some of the compounds of the invention may exist as stereoisomers and/or geometric isomers—e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomeric and/or geometric forms.
  • the present invention contemplates the use of all the individual stereoisomers and geometric isomers of those inhibitor agents, and mixtures thereof.
  • the terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).
  • the present invention also includes all suitable isotopic variations of the agent or a pharmaceutically acceptable salt thereof.
  • An isotopic variation of an agent of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2 H, 3 H, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F and 36 Cl, respectively.
  • isotopic variations of the agent and pharmaceutically acceptable salts thereof are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the agent of the present invention and pharmaceutically acceptable salts thereof of this invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
  • the present invention also includes the use of solvate forms of the compounds of the present invention.
  • the terms used in the claims encompass these forms.
  • the invention furthermore relates to the compounds of the present invention in their various crystalline forms, polymorphic forms and (an)hydrous forms. It is well established within the pharmaceutical industry that chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation form the solvents used in the synthetic preparation of such compounds.
  • the invention further includes the compounds of the present invention in prodrug form.
  • prodrugs are generally compounds of the invention wherein one or more appropriate groups have been modified such that the modification may be reversed upon administration to a human or mammalian subject.
  • Such reversion is usually performed by an enzyme naturally present in such subject, though it is possible for a second agent to be administered together with such a prodrug in order to perform the reversion in vivo.
  • Examples of such modifications include ester (for example, any of those described above), wherein the reversion may be carried out be an esterase etc.
  • Other such systems will be well known to those skilled in the art.
  • compositions of the present invention may be adapted for oral, rectal, vaginal, parenteral, intramuscular, intraperitoneal, intraarterial, intrathecal, intrabronchial, subcutaneous, intradermal, intravenous, nasal, buccal or sublingual routes of administration.
  • compositions For oral administration, particular use is made of compressed tablets, pills, tablets, gellules, drops, and capsules. Preferably, these compositions contain from 1 to 250 mg and more preferably from 10-100 mg, of active ingredient per dose.
  • compositions of the present invention may also be in form of suppositories, pessaries, suspensions, emulsions, lotions, ointments, creams, gels, sprays, solutions or dusting powders.
  • the active ingredient can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin.
  • the active ingredient can also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilisers and preservatives as may be required.
  • Injectable forms may contain between 10-1000 mg, preferably between 10-250 mg, of active ingredient per dose.
  • compositions may be formulated in unit dosage form, i.e., in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose.
  • a person of ordinary skill in the art can easily determine an appropriate dose of one of the instant compositions to administer to a subject without undue experimentation.
  • a physician will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.
  • the dosages disclosed herein are exemplary of the average case. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.
  • one or more doses of 10 to 150 mg/day will be administered to the patient for the treatment of malignancy.
  • the one or more compounds of the invention are administered in combination with one or more other anticancer agents, for example, existing anticancer drugs available on the market.
  • the compounds of the invention may be administered consecutively, simultaneously or sequentially with the one or more other anticancer agents.
  • Anticancer drugs in general are more effective when used in combination.
  • combination therapy is desirable in order to avoid an overlap of major toxicities, mechanism of action and resistance mechanism(s).
  • the major advantages of combining chemotherapeutic drugs are that it may promote additive or possible synergistic effects through biochemical interactions and also may decrease the emergence of resistance in early tumor cells which would have been otherwise responsive to initial chemotherapy with a single agent.
  • An example of the use of biochemical interactions in selecting drug combinations is demonstrated by the administration of leucovorin to increase the binding of an active intracellular metabolite of 5-fluorouracil to its target, thymidylate synthase, thus increasing its cytotoxic effects.
  • Beneficial combinations may be suggested by studying the growth inhibitory activity of the test compounds with agents known or suspected of being valuable in the treatment of a particular cancer initially or cell lines derived from that cancer. This procedure can also be used to determine the order of administration of the agents, i.e. before, simultaneously, or after delivery. Such scheduling may be a feature of all the cycle acting agents identified herein.
  • R 9 , R 10 or R 11 may be a natural or unnatural amino acid.
  • unnatural amino acid refers to a derivative of an amino acid and may for example include alpha and alpha-disubstituted amino acids, N-alkyl amino acids, lactic acid, halide derivatives of natural amino acids such as trifluorotyrosine, p-Cl-phenylalanine, p-Br-phenylalanine, p-I-phenylalanine, L-allyl-glycine, ⁇ -alanine, L- ⁇ -amino butyric acid, L- ⁇ -amino butyric acid, L- ⁇ -amino isobutyric acid, L- ⁇ -amino caproic acid, 7-amino heptanoic acid, L-methionine sulfone, L-norleucine, L-norvaline, p-nitro-L-phenylalanine, L-hydroxyproline, L-thioproline, methyl derivatives of phenylalanine (P
  • the R 9 , R 10 or R 11 groups allow for the immobilisation of the 2-phenylamino-4-heteroaryl-pyrimidine compounds onto a substrate.
  • the R 9 , R 10 or R 11 groups may contain chemical functions that can be used for covalent attachment to solid phases such as functionalised polymers (e.g. agarose, polyacrylamide, polystyrene etc.) as commonly found in matrices (microtitre plate wells, microbeads, membranes, etc.), or used for biochemical assays or affinity chromatography.
  • the R 9 , R 10 or R 11 groups may linked to other small molecules (e.g. biotin) or polypeptides (e.g. antigens), which can be used for non-covalent immobilisation through binding to an immobilised receptor (e.g. avidin or streptavidin in the case of biotin, or a specific antibodies in the case of antigens).
  • an immobilised receptor e.g. avidin or streptavi
  • Another aspect of the invention relates to the use of a compound of the invention as defined hereinabove in an assay for identifying further candidate compounds that influence the activity of one or more of the following: a CDK, an aurora kinase, GSK-3, PLK and/or a tyrosine kinase.
  • the assay is capable of identifying candidate compounds that are capable of inhibiting one or more of a CDK enzyme, an aurora kinase, a tyrosine kinase, GSK or a PLK enzyme.
  • the assay is a competitive binding assay.
  • the candidate compound is generated by conventional SAR modification of a compound of the invention.
  • conventional SAR modification refers to standard methods known in the art for varying a given compound by way of chemical derivatisation.
  • the identified compound may act as a model (for example, a template) for the development of other compounds.
  • the compounds employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition of activity or the formation of binding complexes between the compound and the agent being tested may be measured.
  • the assay of the present invention may be a screen, whereby a number of agents are tested.
  • the assay method of the present invention is a high through-put screen.
  • This invention also contemplates the use of competitive drag screening assays in which neutralizing antibodies capable of binding a compound specifically compete with a test compound for binding to a compound.
  • HTS high throughput screening
  • the competitive binding assay comprises contacting a compound of the invention with a CDK, an aurora kinase, GSK-3, PLK and/or a tyrosine kinase in the presence of a known substrate of said CDK enzyme and detecting any change in the interaction between said CDK enzyme and said known substrate.
  • a further aspect of the invention provides a method of detecting the binding of a tigand to a CDK, an aurora kinase, GSK-3, PLK or a tyrosine kinase enzyme, said method comprising the steps of:
  • One aspect of the invention relates to a process comprising the steps of:
  • Another aspect of the invention provides a process comprising the steps of:
  • Another aspect of the invention provides a process comprising the steps of:
  • the invention also relates to a ligand identified by the method described hereinabove.
  • Yet another aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a ligand identified by the method described hereinabove.
  • Another aspect of the invention relates to the use of a ligand identified by the method described hereinabove in the preparation of a pharmaceutical composition for use in the treatment of proliferative disorders.
  • the above methods may be used to screen for a ligand useful as an inhibitor of one or more CDK enzymes.
  • solubilising moieties can be achieved in a number of different ways known in the art (Wermuth C G. Preparation of water-soluble compounds by covalent attachment of solubilizing moieties. In: Practice of Medicinal Chemistry, Academic Press: London, UK, 1996; pp 755-776).
  • amino substituents in 2-phenylamino-4-heteroaryl-pyrimidine derivatives, or their synthetic precursors can be acylated or alkylated with carbonyl functions in appropriate solubilising moiety precursors.
  • carbonyl groups in the 2-phenylamino-4-heteroaryl-pyrimidine derivatives can be aminated or alkylated with appropriate solubilising moiety precursors.
  • Halogen groups on aromatic C in phenylamino-4-heteroaryl-pyrimidines or precursors can be substituted through nucleophilic groups in solubilising moiety precursors.
  • Suitable 2-phenylamino-4-heteroaryl-pyrimidine precursors may be prepared in accordance with the teachings of Fischer et al (WO 01/072745 and WO 03/029248; Cyclacel Limited).
  • the compounds of the invention may be prepared in accordance with the methods disclosed in WO 01/072745 and WO 03/029248.
  • N′-[5-(3-dimethylamino-acryloyl)-4-methyl-thiazol-2-yl]-N,N-dimethyl-formamidine N-(4-guanidino-benzyl)-acetamide nitrate. Yellow solid.
  • RP-HPLC: t R 10.9 min (0-60% MeCN, purity >90%).
  • N-(2-Methoxy-ethyl)-4-[4-(4-methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-benzenesulfonamide (40).
  • 4-guanidino-N-(2-methoxy-ethyl)-benzenesulfonamide nitrate. Yellow solid.
  • N,N-diethyl-4-guanidino-benzene-sulfonamide Yellow solid.
  • N-Acetyl-3-[4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-benzenesulfonamide 64.
  • N1-[5-(3-dimethylamino-acryloyl)-4-methyl-thiazol-2-yl]-N,N-dimethyl-formamidine N-acetyl-3-guanidino-benzenesulfonamide. Yellow solid.
  • RP-HPLC: t R 11.9 min (0-60% MeCN; purity 96%).
  • RP-HPLC: t R 17.4 min (0-60% MeCN; purity 99%).
  • RP-HPLC: t R 16.6 min (0-60% MeCN; purity 99%).
  • kinase assays The compounds of the invention above were investigated for their ability to inhibit the enzymatic activity of various protein kinases (Table 2). This was achieved by measurement of incorporation of radioactive phosphate from ATP into appropriate polypeptide substrates. Recombinant protein kinases and kinase complexes were produced or obtained commercially. Assays were performed using 96-well plates and appropriate assay buffers (typically 25 mM ⁇ -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na 3 VO 3 , pH 7.4), into which were added 2-4 ⁇ g of active enzyme with appropriate substrates.
  • assay buffers typically 25 mM ⁇ -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na 3 VO 3 , pH 7.4
  • the reactions were initiated by addition of Mg/ATP mix (15 mM MgCl 2 +100 ⁇ M ATP with 30-50 kBq per well of [ ⁇ - 32 P]-ATP) and mixtures incubated as required at 30° C. Reactions were stopped on ice, followed by filtration through p81 filterplates or GF/C filterplates (Whatman Polyfiltronics, Kent, UK). After washing 3 times with 75 mM aq orthophosphoric acid, plates were dried, scintillant added and incorporated radioactivity measured in a scintillation counter (TopCount, Packard Instruments, Pangbourne, Berks, UK).
  • CDK 7 and 9 assays were incubated for 45 min at 30° C.
  • CTD peptide substrate biotinyl-Abx-(Tyr-Ser-Pro-Thr-Ser-Pro-Ser) 4 -NH 2 ; 1-2 mg/mL
  • recombinant human CDK7/cyclin H, CDK9/cyclin T1, or CDK9/cyclin K (0.5-2 ⁇ g) were incubated for 45 min at 30° C.
  • test compound in 20 mM MOPS pH 7.2, 25 mM ⁇ -glycerophosphate, 5 mM EGTA, 1 mM DTT, 1 mM sodium vanadate, 15 mM MgCl 2 , and 100 ⁇ M ATP (containing a trace amount of 32 P ⁇ ATP) in a total volume of 25 ⁇ L in a 96-well microtiter plate.
  • the reaction was stopped by placing the plate on ice for 2 min. Avidin (50 ⁇ g) was added to each well, and the plate was incubated at room temp for 30 min.
  • the samples were transferred to a 96-well P81 filter plate, and washed (4 ⁇ 200 ⁇ L per well) with 75 mM phosphoric acid.
  • Microscint 40 scintillation liquid 50 ⁇ L was added to each well, and the amount of 32 P incorporation for each sample was measured using a Packard Topcount microplate scintillation counter.
  • Aurora-A (human) kinase assay This was achieved by measurement of incorporation of radioactive phosphate from ATP into Kemptide substrate (LRRASLG), upon phosphorylation by commercially obtained aurora-A kinase. Assays were performed using 96-well plates and appropriate assay buffers (8 mM MOPS, 0.2 mM EDTA, pH 7.0), into which were added 5-10 ng of active enzyme with 200 ⁇ M substrate (Kemptide). The reactions were initiated by addition of Mg/ATP mix (10 mM MgAcetate+15 ⁇ M ATP with 30-50 kBq per well of [ ⁇ - 33 P]-ATP) and mixtures incubated for 40 min at room temperature.
  • Mg/ATP mix (10 mM MgAcetate+15 ⁇ M ATP with 30-50 kBq per well of [ ⁇ - 33 P]-ATP
  • MTT cytotoxicity assay The compounds of the invention were subjected to a standard cellular proliferation assay using human tumour cell lines obtained from the ATCC (American Type Culture Collection, 10801 University Boulevard, Manessas, Va. 20110-2209, USA). Standard 72-h MTT (thiazolyl blue; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays were performed (Haselsberger, K.; Peterson, D. C.; Thomas, D. G.; Darling, J. L. Anti Cancer Drugs 1996, 7, 331-8; Loveland, B. E.; Johns, T. G.; Mackay, I. R.; Vaillant, R; Wang, Z.
  • MTT solution was removed and cells again washed with 200 ⁇ L PBS.
  • MTT dye was solubilised with 200 ⁇ L per well of DMSO with agitation. Absorbance was read at 540 nm and data analysed using curve-fitting software (GraphPad Prism version 3.00 for Windows, GraphPad Software, San Diego Calif. USA) to determine IC 50 values (concentration of test compound which inhibits cell growth by 50%).
  • Representative compounds of the present invention were tested for antiviral activity against HIV-1 in human peripheral blood mononuclear cells (PBMCs) using the clinical pediatric HIV strain RoJo or WeJo.
  • PBMCs peripheral blood mononuclear cells
  • Antiviral activity was tested for from 6-9 log 10 serial dilutions of a 100 ⁇ M compound stock solution in DMSO. The following parameters were derived: IC 50 and IC 90 (concentrations inhibiting virus replication by 50 and 90%, respectively, TC 50 (concentration decreasing cell viability by 50%), and TI (therapeutic index: TC 50 /IC 50 ).
  • DPBS Dulbecco's Phosphate Buffered Saline
  • LSM Lymphocyte Separation Medium
  • PBMCs Banded PBMCs were gently aspirated from the resulting interface and subsequently washed with PBS by low speed centrifugation. After the final wash, cells were enumerated by trypan blue exclusion and re-suspended in RPMI 1640 supplemented with fetal bovine serum (FBS), and L-glutamine, Phytohemagglutinin (PHA-P, Sigma). The cells were allowed to incubate at 37° C. After incubation, PBMCs were centrifuged and resuspended in RPMI 1640 with FBS, L-glutamine, penicillin, streptomycin, gentamycin, and recombinant human IL-2 (R&D Systems, Inc).
  • FBS fetal bovine serum
  • PHA-P Phytohemagglutinin
  • IL-2 is included in the culture medium to maintain the cell division initiated by the PHA mitogemc stimulation.
  • PBMCs were maintained in this with bi-weekly medium changes until used in the assay protocol.
  • Cells were kept in culture for a maximum of two weeks before being deemed too old for use in assays and discarded.
  • Monocytes were depleted from the culture as the result of adherence to the tissue culture flask.
  • PHA-P stimulated cells from at least two normal donors were pooled, diluted and plated in the interior wells of a 96-well round bottom microplate. Pooling of mononuclear cells from more than one donor was used to minimise the variability observed between individual donors, which results from quantitative and qualitative differences in HIV infection and overall response to the PHA and IL-2 of primary lymphocyte populations.
  • Each plate contained virus/cell control wells (cells plus virus), experimental wells (drug plus cells plus virus) and compound control wells (drug plus media without cells, necessary for MTS monitoring of cytotoxicity). Since HIV-1 is not cytopathic to PBMCs, this allows the use of the same assay plate for both antiviral activity and cytotoxicity measurements.
  • Test drug dilutions were prepared in microtiter tubes and each concentration was placed in appropriate wells using the standard format. A predetermined dilution of virus stock was placed in each test well (final MOI ⁇ 0.1). The PBMC cultures were maintained for seven days following infection at 37° C., 5% CO 2 . After this period, cell-free supernatant samples were collected for analysis of reverse transcriptase activity and/or HIV p24 content. Following removal of supernatant samples, compound cytotoxicity was measured by addition of MTS to the plates for determination of cell viability. Wells were also examined microscopically and any abnormalities were noted.
  • Reverse transcriptase activity assay A microtiter plate-based reverse transcriptase (RT) reaction was utilised (Buckheit et al., ADDS Research and Human Retroviruses 7:295-302, 1991). Tritiated thymidine triphosphate ( 3 H-TTP, 80 Ci/mmol, NEN) was received in 1:1 dH 2 /Ethanol at 1 mCi/mL. Poly rA:oligo dT template:primer (Pharmacia) was prepared as a stock solution, followed by aliquoting and storage at ⁇ 20° C. The RT reaction buffer was prepared fresh on a daily basis.
  • RT reverse transcriptase activity assay
  • the final reaction mixture was prepared by combining 3 H-TTP, dH 2 O, poly rA:oligo dT stock and reaction buffer. This reaction mixture was placed in a round bottom microtiter plate and supernatant containing virus was added and mixed. The plate was incubated at 37° C. for 60 minutes. Following incubation, the reaction volume was spotted onto DE81 filter-mats (Wallac), in a sodium phosphate buffer or 2 ⁇ SSC (Life Technologies). Next they were washed in distilled water, in 70% ethanol, and then dried. Incorporated radioactivity (counts per minute, CPM) was quantified using standard liquid scintillation techniques.
  • the kinases were assayed at the following ATP concentrations: SAPK4, PKB ⁇ ph, GSK3b, SAPK3, CK2, MKK1, PIM2, IKKB, ERK8, and PRK2 at 5 ⁇ M; JNK, PRAK, ROCK-II, SAPK2b, CDK2, CHK1, MSK1, CSK, P70S6K, PKA, CK1, MAPKAP-K2, SGK, PKCa, PDK1, NEK 7, and MAPKAP-K3 at 20 ⁇ M; SAPK2a, LCK, AMPK, MAPK2, DYRK1a, MAPKAP-K1a, NEK-6, NEK2a, PBK, CAMK-1, SRPK-1, JNK3, MNK2, RSK2, MNK1, PKBB, and SmMLCK at 50 ⁇ M.
  • the ATP concentration was 100 ⁇ M throughout.
  • cyclin B cyclin A cycline E cyclin D1 cyclin H cyclin T1 GSK-3b Flt3 a kinase 1 6.0 5.5 6.9 2 5.9 5.8 6.5 6.1 6.5 6.2 3 5.5 5.7 5.3 7.7 7.7 4 6.3 6.0 6.5 5.9 6.0 6.6 6.4 6.6 5 5.9 6.7 6.8 6.8 6.6 7.9 6.7 7.3 7.5 6 6.0 6.4 7.0 6.7 6.9 8.1 7.3 6.9 7 5.5 5.6 6.4 6.0 6.2 6.7 7.9 6.7 8 5.3 5.3 5.7 5.6 5.7 6.3 4.9 7.3 4.4 9 6.2 6.0 6.8 6.6 5.3 6.3 5.7 6.8 10 5.2 5.8 5.2 6.5 5.2 6.8 5.7 11 5.8 5.8 6.8 5.9 6.2 5.9 5.8 6.7 12 6.2 6.3 7.2 6.2 6.7 7.0 5.7 6.1 6.6 13 6.2 6.9 7.4 7.2 6.7 7.6 7.5 7.8 14 6.4 6.2 7.4 6.9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
US11/596,740 2004-05-26 2005-05-26 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders Abandoned US20090137572A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0411791.7A GB0411791D0 (en) 2004-05-26 2004-05-26 Compounds
GB0411791.7 2004-05-26
PCT/GB2005/002134 WO2005116025A2 (en) 2004-05-26 2005-05-26 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
US20090137572A1 true US20090137572A1 (en) 2009-05-28

Family

ID=32671118

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/596,740 Abandoned US20090137572A1 (en) 2004-05-26 2005-05-26 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders

Country Status (11)

Country Link
US (1) US20090137572A1 (enrdf_load_stackoverflow)
EP (1) EP1756098A2 (enrdf_load_stackoverflow)
JP (1) JP5026259B2 (enrdf_load_stackoverflow)
CN (1) CN1989138A (enrdf_load_stackoverflow)
AU (1) AU2005247682A1 (enrdf_load_stackoverflow)
BR (1) BRPI0511616A (enrdf_load_stackoverflow)
CA (1) CA2566051A1 (enrdf_load_stackoverflow)
GB (1) GB0411791D0 (enrdf_load_stackoverflow)
IL (1) IL179508A0 (enrdf_load_stackoverflow)
MX (1) MXPA06013632A (enrdf_load_stackoverflow)
WO (1) WO2005116025A2 (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041582A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US20180222900A1 (en) * 2015-08-04 2018-08-09 University Of South Australia N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1490354A1 (en) 2002-03-09 2004-12-29 Astrazeneca AB 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
CA2583812A1 (en) * 2004-10-28 2006-05-11 Irm Llc Compounds and compositions as hedgehog pathway modulators
CN101203500B (zh) * 2005-01-25 2013-08-21 格利尼公司 取代的芳胺化合物和它们作为5-ht6调节剂的用途
US7968538B2 (en) 2005-01-25 2011-06-28 Galenea Corp. Substituted arylamine compounds and methods of treatment
JP5199885B2 (ja) 2006-01-18 2013-05-15 アムジエン・インコーポレーテツド プロテインキナーゼｂ（ｐｋｂ）阻害剤としてのチアゾール化合物
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
WO2007132220A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
WO2009011880A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
EP2197876A1 (en) * 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
EP2212297B1 (en) * 2007-10-12 2011-05-25 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
EP2231625A4 (en) * 2007-12-13 2010-12-29 Glaxosmithkline Llc KINASE INHIBITORS BASED ON THIAZOLE AND OXAZOLE
ES2617622T3 (es) 2008-02-15 2017-06-19 Rigel Pharmaceuticals, Inc. Compuestos de pirimidin-2-amina y su uso como inhibidores de JAK cinasas
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
EP2498608A4 (en) * 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US9199979B2 (en) * 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
US9382239B2 (en) * 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
EP3489232A3 (en) 2014-04-04 2019-07-31 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
US11325900B2 (en) 2018-01-15 2022-05-10 Aucentra Holdings Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN111039941B (zh) * 2018-10-12 2023-03-21 上海医药集团股份有限公司 一种含氮杂环化合物、其制备方法及应用
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2024259116A1 (en) * 2023-06-14 2024-12-19 Prothena Biosciences Limited 5-(cinnolin-6-yl)thiazole compounds for treating neurological disorders
CN116903592B (zh) * 2023-07-13 2025-08-01 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US6107301A (en) * 1993-10-12 2000-08-22 Dupont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
US6221873B1 (en) * 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
WO2001072745A1 (en) * 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
US6417185B1 (en) * 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6569833B1 (en) * 1995-09-21 2003-05-27 Cyclacel Limited Cyclin dependent kinase binding peptides
US6703395B2 (en) * 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20040181066A1 (en) * 2001-08-01 2004-09-16 Fraley Mark E. Tyrosine kinase inhibitors
US20040259894A1 (en) * 2001-09-28 2004-12-23 Shudong Wang N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds
US20050192300A1 (en) * 2002-11-14 2005-09-01 Shudong Wang Pyrimidine compounds
US6962792B1 (en) * 1996-05-08 2005-11-08 Cyclacel Limited Methods and means for inhibition of Cdk4 activity
US20050282843A1 (en) * 2002-12-19 2005-12-22 Shudong Wang Therapeutic applications of 2-substituted 4-heteroarylpyrimidines
US20050288307A1 (en) * 2002-11-14 2005-12-29 Shudong Wang Anti-viral compounds
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20060241297A1 (en) * 2003-07-30 2006-10-26 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
US20070021419A1 (en) * 2003-07-30 2007-01-25 Cyclacel Limited 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors
US20070021452A1 (en) * 2003-10-21 2007-01-25 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
US20070185134A1 (en) * 2001-03-29 2007-08-09 Cyclacel Limited Inhibitors of cyclin dependent kinases as anti-cancer agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446756C (en) * 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
CA2523125A1 (en) * 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
WO2005113550A1 (ja) * 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation アミノピリミジン誘導体及びその医薬としての用途

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US6107301A (en) * 1993-10-12 2000-08-22 Dupont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
US6569833B1 (en) * 1995-09-21 2003-05-27 Cyclacel Limited Cyclin dependent kinase binding peptides
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US6962792B1 (en) * 1996-05-08 2005-11-08 Cyclacel Limited Methods and means for inhibition of Cdk4 activity
US6703395B2 (en) * 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US6221873B1 (en) * 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US6417185B1 (en) * 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6699854B2 (en) * 2000-03-29 2004-03-02 Cyclacel Limited Anti-cancer compounds
US6531479B2 (en) * 2000-03-29 2003-03-11 Cyclacel Limited Anti-cancer compounds
US20020019404A1 (en) * 2000-03-29 2002-02-14 Shudong Wang Anti-cancer compounds
WO2001072745A1 (en) * 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
US7262202B2 (en) * 2001-03-29 2007-08-28 Cyclacel Limited Inhibitors of cyclin dependent kinases as anti-cancer agent
US20070185134A1 (en) * 2001-03-29 2007-08-09 Cyclacel Limited Inhibitors of cyclin dependent kinases as anti-cancer agent
US20040181066A1 (en) * 2001-08-01 2004-09-16 Fraley Mark E. Tyrosine kinase inhibitors
US20040259894A1 (en) * 2001-09-28 2004-12-23 Shudong Wang N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds
US20060199830A1 (en) * 2001-09-28 2006-09-07 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds
US7427627B2 (en) * 2001-09-28 2008-09-23 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds
US20050288307A1 (en) * 2002-11-14 2005-12-29 Shudong Wang Anti-viral compounds
US20050192300A1 (en) * 2002-11-14 2005-09-01 Shudong Wang Pyrimidine compounds
US20050282843A1 (en) * 2002-12-19 2005-12-22 Shudong Wang Therapeutic applications of 2-substituted 4-heteroarylpyrimidines
US20060241297A1 (en) * 2003-07-30 2006-10-26 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
US20070021419A1 (en) * 2003-07-30 2007-01-25 Cyclacel Limited 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors
US20070021452A1 (en) * 2003-10-21 2007-01-25 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
McMahon et al *
Pinedo et al *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041582A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US10172844B2 (en) 2011-10-20 2019-01-08 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US11351161B2 (en) 2011-10-20 2022-06-07 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
US11020404B2 (en) 2014-10-14 2021-06-01 The Regents of the University of California, Davis Use of CDK9 and BRD4 inhibitors to inhibit inflammation
US20180222900A1 (en) * 2015-08-04 2018-08-09 University Of South Australia N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
US10479785B2 (en) * 2015-08-04 2019-11-19 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
USRE49850E1 (en) * 2015-08-04 2024-02-27 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
US11970491B2 (en) 2015-08-04 2024-04-30 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds

Also Published As

Publication number Publication date
CA2566051A1 (en) 2005-12-08
EP1756098A2 (en) 2007-02-28
CN1989138A (zh) 2007-06-27
IL179508A0 (en) 2007-05-15
GB0411791D0 (en) 2004-06-30
WO2005116025A3 (en) 2006-02-23
JP5026259B2 (ja) 2012-09-12
MXPA06013632A (es) 2007-03-23
WO2005116025A2 (en) 2005-12-08
AU2005247682A1 (en) 2005-12-08
BRPI0511616A (pt) 2008-01-02
JP2008500320A (ja) 2008-01-10

Similar Documents

Publication Publication Date Title
US20090137572A1 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
US7897605B2 (en) Pyrimidine compounds
US7902361B2 (en) Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy
EP1751146B1 (en) Pyridinyl- or pyrimidinyl thiazoles with protein kinase inhibiting activity
US20070021419A1 (en) 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors
US20060241297A1 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
US20090318446A1 (en) 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy
JP4495963B2 (ja) 抗増殖性化合物としてのｎ−（４−（４−メチルチアゾール−５−イル）ピリミジン−２−イル）−ｎ−フェニルアミン類
US20090215805A1 (en) 4-Heteroaryl Pyrimidine Derivatives and use thereof as Protein Kinase Inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: CYCLACEL LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WANG, SHUDONG;REEL/FRAME:021837/0501

Effective date: 20080915

AS Assignment

Owner name: CYCLACEL LIMITED, UNITED KINGDOM

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTORS WOOD, DUNCAN, MEADES, GIBSON, MCLACHLAN AND FISCHER WERE INADVERTENTLY OMITTED FROM THE ORIGINAL FILING. PREVIOUSLY RECORDED ON REEL 021837 FRAME 0501;ASSIGNORS:WANG, SHUDONG;WOOD, GAVIN;DUNCAN, KENNETH;AND OTHERS;REEL/FRAME:021848/0533;SIGNING DATES FROM 20080911 TO 20080924

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION